Irene Caesar, Ph.D. is a President and Founder of WAVE GENOME. She has founded WAVE GENOME in 2010 in Stamford, Connecticut, to lead the global QUANTUM LEAP in Laser Bioholography, Holonet (Holographic Biointernet), holographic drugs, Remote Bioengineering, and bioelectronics. WAVE GENOME is an American company, located now in Manchester, Connecticut, which is proud to be the leading competitor of major players in the field of bioelectronics, such as Elon Musk with his Neuralink, and Google with its R&D race for bioelectronic drugs. WAVE GENOME is ahead of Google for 8 years of actual sales and 50 years beyond R&D.
For developing and producing its products and clinical trials, WAVE GENOME is teaming with the most advanced scientists all over the world, e.g., Moscow Bauman Russian State Technical University, and the Scientific Research Institute for National Security in Moscow. WAVE GENOME pioneered the transfer of bioholograms of drugs upon electret-based chips via laser – the idea offered by Wave Genome to the above mentioned institutions.
Dr. Caesar holds a doctorate degree in philosophy of science, and is an author of three books. She is an author of the structuralist theory of wave genome. In August 2012, Dr. Caesar co-founded the Consortium MATRIX CITY with the Institute for National Security in Moscow for building human settlements of a completely new type, with the application of the information-wave technologies of the Quantum Leap.
In May 2013, Dr. Caesar formulated the principles of the Quantum Internet, based upon her principle of the uniqueness of the non-local wave matrices (Irene Caesar, 2012), and instantaneous transmission between all tokens of the same unique non-local wave matrix. Dr. Caesar presented her project MATRIX CITY in her public lecture at the Harriman Institute of the Columbia University in September 2012.
Irene Caesar, Ph.D., is regularly presenting her research at the major Science Conferences all over the world.
In November 2017, Dr. Caesar was invited to head the Neural Engineering Section at the BIT’s 1st WORLD CONGRESS OF BIOMEDICAL ENGINEERING, Theme: Co-creating a New Future of Biomedicine, November 9-11, 2017, in Xi’an, China.